skip to content


Issue No. 27 | July 2, 2010

News and Features

NIH Solicits Proposals for HIV Research Funding Opportunity

“The National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Mental Health (NIMH), both part of the National Institutes of Health, … announced a new research funding opportunity to design, develop and evaluate new strategies for curing HIV infection through partnerships among government, industry and academia. NIAID and NIMH will fund one or two grants with a total of $8.5 million per year for five years.

“This request for applications (RFA), called “Martin Delaney Collaboratory: Towards an HIV-1 Cure,” is named in honor of influential AIDS activist Martin Delaney, who died of liver cancer in 2009. …

“Although individuals infected with HIV may effectively control virus levels with antiretroviral therapy and maintain relatively good health, the virus is never fully eliminated from the cells and tissues it has infected. Researchers need to better understand where these reservoirs of HIV are located, how they are established and maintained, and how to eliminate them. The new collaboratory aims to do this by supporting basic and clinical research...

“NIAID and NIMH will accept applications to the Martin Delaney Collaboratory through November 4, 2010.”
More information is available:

FDA Updates Isentress (Raltegravir) Label with 96-Week Safety/Efficacy Results

“On June 29, 2010, the Isentress (raltegravir potassium) tablet label was updated with the Week 96 safety and efficacy results in treatment-naïve and treatment-experienced patients.

"In the treatment-naïve trial 021, the proportion of subjects with HIV RNA < 50 copies/mL was 82% for the Isentress 400 mg twice daily regimen compared to 78% for the Efavirenz arm. The treatment difference and 95% CI was 3.8% (-2.8%, 10.4%).

"In the treatment-experienced pooled analysis of trials 018 and 019, the proportion of subjects with HIV RNA < 50 copies/mL was 55% for the Isentress 400 mg twice daily + optimized background regimen compared to 27% for the optimized background regimen arm.”

The complete revised label will be available on the FDA Web site.

More information is available:

CDC Releases Three Reports on HIV in the United States

CDC recently released an HIV special surveillance report and two Morbidity and Mortality Weekly Reports (MMWRs) about HIV: